To expand the therapeutic potential of this approach for neurodegenerative diseases, Fujita et al. identified a notable up—regulation of HMGB1 in both patients with AD and APP/PS1 transgenic mouse models via gene expression profiling. This evidence concerns the gene HMGB1 and Alzheimer disease.